Cargando…

Feasibility of intravitreal injections and ophthalmic safety assessment in marmoset (Callithrix jacchus) monkeys

To safeguard patients, regulatory authorities require that new drugs that are to be given by the intravitreal (IVT) route are assessed for their safety in a laboratory species using the same route of administration. Due to the high similarity of ocular morphology and physiology between humans and no...

Descripción completa

Detalles Bibliográficos
Autores principales: Korbmacher, Birgit, Atorf, Jenny, Fridrichs-Gromoll, Stephanie, Hill, Marilyn, Korte, Sven, Kremers, Jan, Mansfield, Keith, Mecklenburg, Lars, Pilling, Andrew, Wiederhold, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Copernicus GmbH 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041524/
https://www.ncbi.nlm.nih.gov/pubmed/32110696
http://dx.doi.org/10.5194/pb-4-93-2017
_version_ 1783501167598239744
author Korbmacher, Birgit
Atorf, Jenny
Fridrichs-Gromoll, Stephanie
Hill, Marilyn
Korte, Sven
Kremers, Jan
Mansfield, Keith
Mecklenburg, Lars
Pilling, Andrew
Wiederhold, Andreas
author_facet Korbmacher, Birgit
Atorf, Jenny
Fridrichs-Gromoll, Stephanie
Hill, Marilyn
Korte, Sven
Kremers, Jan
Mansfield, Keith
Mecklenburg, Lars
Pilling, Andrew
Wiederhold, Andreas
author_sort Korbmacher, Birgit
collection PubMed
description To safeguard patients, regulatory authorities require that new drugs that are to be given by the intravitreal (IVT) route are assessed for their safety in a laboratory species using the same route of administration. Due to the high similarity of ocular morphology and physiology between humans and nonhuman primates (NHPs) and due to the species specificity of many biotherapeutics, the monkey is often the only appropriate model. To this end, intravitreal administration and assessment of ocular toxicity are well established in cynomolgus monkeys (Macaca fascicularis). In contrast, the common marmoset monkey (Callithrix jacchus) is not a standard model for ocular toxicity studies due to its general sensitivity to laboratory investigations and small eye size. It was the purpose of the present work to study whether the marmoset is a useful alternative to the cynomolgus monkey for use in intravitreal toxicological studies. Six marmoset monkeys received repeated (every 2 weeks for a total of four doses) intravitreal injections of 10 or 20  [Formula: see text] L of a placebo. The animals were assessed for measurements of intraocular pressure (IOP), standard ophthalmological investigations and electroretinography (ERG). At the end of the dosing period, the animals were sacrificed and the eyes were evaluated histologically. ERG revealed similar results when comparing predose to end-of-study data, and there was no difference between the two dose volumes. A transient increase in the IOP was seen immediately after dosing, which was more pronounced after dosing of 20  [Formula: see text] L compared to 10  [Formula: see text] L. Ophthalmologic and microscopic observations did not show any significant changes. Therefore, it can be concluded that 10  [Formula: see text] L as well as 20  [Formula: see text] L intravitreal injections of a placebo are well tolerated in the marmoset. These results demonstrate that the common marmoset is an alternative to the cynomolgus monkey for intravitreal toxicity testing.
format Online
Article
Text
id pubmed-7041524
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Copernicus GmbH
record_format MEDLINE/PubMed
spelling pubmed-70415242020-02-27 Feasibility of intravitreal injections and ophthalmic safety assessment in marmoset (Callithrix jacchus) monkeys Korbmacher, Birgit Atorf, Jenny Fridrichs-Gromoll, Stephanie Hill, Marilyn Korte, Sven Kremers, Jan Mansfield, Keith Mecklenburg, Lars Pilling, Andrew Wiederhold, Andreas Primate Biol Research Article To safeguard patients, regulatory authorities require that new drugs that are to be given by the intravitreal (IVT) route are assessed for their safety in a laboratory species using the same route of administration. Due to the high similarity of ocular morphology and physiology between humans and nonhuman primates (NHPs) and due to the species specificity of many biotherapeutics, the monkey is often the only appropriate model. To this end, intravitreal administration and assessment of ocular toxicity are well established in cynomolgus monkeys (Macaca fascicularis). In contrast, the common marmoset monkey (Callithrix jacchus) is not a standard model for ocular toxicity studies due to its general sensitivity to laboratory investigations and small eye size. It was the purpose of the present work to study whether the marmoset is a useful alternative to the cynomolgus monkey for use in intravitreal toxicological studies. Six marmoset monkeys received repeated (every 2 weeks for a total of four doses) intravitreal injections of 10 or 20  [Formula: see text] L of a placebo. The animals were assessed for measurements of intraocular pressure (IOP), standard ophthalmological investigations and electroretinography (ERG). At the end of the dosing period, the animals were sacrificed and the eyes were evaluated histologically. ERG revealed similar results when comparing predose to end-of-study data, and there was no difference between the two dose volumes. A transient increase in the IOP was seen immediately after dosing, which was more pronounced after dosing of 20  [Formula: see text] L compared to 10  [Formula: see text] L. Ophthalmologic and microscopic observations did not show any significant changes. Therefore, it can be concluded that 10  [Formula: see text] L as well as 20  [Formula: see text] L intravitreal injections of a placebo are well tolerated in the marmoset. These results demonstrate that the common marmoset is an alternative to the cynomolgus monkey for intravitreal toxicity testing. Copernicus GmbH 2017-04-28 /pmc/articles/PMC7041524/ /pubmed/32110696 http://dx.doi.org/10.5194/pb-4-93-2017 Text en Copyright: © 2017 Birgit Korbmacher et al. This work is licensed under the Creative Commons Attribution 3.0 Unported License. To view a copy of this licence, visit https://creativecommons.org/licenses/by/3.0/
spellingShingle Research Article
Korbmacher, Birgit
Atorf, Jenny
Fridrichs-Gromoll, Stephanie
Hill, Marilyn
Korte, Sven
Kremers, Jan
Mansfield, Keith
Mecklenburg, Lars
Pilling, Andrew
Wiederhold, Andreas
Feasibility of intravitreal injections and ophthalmic safety assessment in marmoset (Callithrix jacchus) monkeys
title Feasibility of intravitreal injections and ophthalmic safety assessment in marmoset (Callithrix jacchus) monkeys
title_full Feasibility of intravitreal injections and ophthalmic safety assessment in marmoset (Callithrix jacchus) monkeys
title_fullStr Feasibility of intravitreal injections and ophthalmic safety assessment in marmoset (Callithrix jacchus) monkeys
title_full_unstemmed Feasibility of intravitreal injections and ophthalmic safety assessment in marmoset (Callithrix jacchus) monkeys
title_short Feasibility of intravitreal injections and ophthalmic safety assessment in marmoset (Callithrix jacchus) monkeys
title_sort feasibility of intravitreal injections and ophthalmic safety assessment in marmoset (callithrix jacchus) monkeys
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041524/
https://www.ncbi.nlm.nih.gov/pubmed/32110696
http://dx.doi.org/10.5194/pb-4-93-2017
work_keys_str_mv AT korbmacherbirgit feasibilityofintravitrealinjectionsandophthalmicsafetyassessmentinmarmosetcallithrixjacchusmonkeys
AT atorfjenny feasibilityofintravitrealinjectionsandophthalmicsafetyassessmentinmarmosetcallithrixjacchusmonkeys
AT fridrichsgromollstephanie feasibilityofintravitrealinjectionsandophthalmicsafetyassessmentinmarmosetcallithrixjacchusmonkeys
AT hillmarilyn feasibilityofintravitrealinjectionsandophthalmicsafetyassessmentinmarmosetcallithrixjacchusmonkeys
AT kortesven feasibilityofintravitrealinjectionsandophthalmicsafetyassessmentinmarmosetcallithrixjacchusmonkeys
AT kremersjan feasibilityofintravitrealinjectionsandophthalmicsafetyassessmentinmarmosetcallithrixjacchusmonkeys
AT mansfieldkeith feasibilityofintravitrealinjectionsandophthalmicsafetyassessmentinmarmosetcallithrixjacchusmonkeys
AT mecklenburglars feasibilityofintravitrealinjectionsandophthalmicsafetyassessmentinmarmosetcallithrixjacchusmonkeys
AT pillingandrew feasibilityofintravitrealinjectionsandophthalmicsafetyassessmentinmarmosetcallithrixjacchusmonkeys
AT wiederholdandreas feasibilityofintravitrealinjectionsandophthalmicsafetyassessmentinmarmosetcallithrixjacchusmonkeys